Psyence Group Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jody Aufrichtig
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 200 Bay Street Toronto ON Canada M5J 2J1
- IPO Date
- May 31, 2022
- CIK
- 0002009573
- Website
- psyence.com
- Similar Companies
- Business
- Psyence Group Inc. (PSYGF) develops and commercializes psychedelic therapeutics and related wellness products focused on mental health treatments, including psilocybin-based medicines for conditions such as anxiety, depression, and end-of-life distress; it also produces functional mushroom supplements and beverages under brands targeting consumer wellness markets. The company operates in the biotechnology and wellness sectors, serving healthcare providers, patients, and direct-to-consumer channels primarily in North America with expansion into Europe and Australia. Founded in 2021 and headquartered in Toronto, Canada, Psyence Group maintains subsidiaries for medicinal research, consumer products, and biomedical production. Recent developments include the 2024 launch of its Psyence Medicines division to accelerate clinical trials for novel psilocybin therapies; a strategic partnership with a leading European clinic network for distribution; and a C$10 million funding round in early 2025 to support Phase 2 trials and manufacturing scale-up.
Company News
GoldCoast Resource Corp. Announces Trading Halt Pending Clarification from Government of Ghana
GoldCoast Resource Corp. Clarifies Media Reports and Confirms Offshore Licenses Remain in Good Standing
Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine
GoldCoast Resource Corp. to Commence Trading on the OTCQB Venture Market
Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
Psyence BioMed Announces Strategic Ibogaine Investment
Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development
Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development
Psyence Group Inc. Announces Results of Annual General and Special Meeting of Shareholders
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
Psyence Group Announces GoldCoast Resource Closes Second Tranche of Offering
Psyence Group Inc. Provides Update on Proposed Amalgamation with GoldCoast Resource Corp.
Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
Psyence Group Inc. Enters into Amending Agreement to Extend Amalgamation Timeline with GoldCoast Resource Corp.
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment